Tonix Pharmaceuticals (NASDAQ:TNXP) Issues Quarterly Earnings Results

Tonix Pharmaceuticals (NASDAQ:TNXP) posted its earnings results on Thursday. The company reported ($4.15) EPS for the quarter, missing analysts’ consensus estimates of ($3.16) by ($0.99), FiscalAI reports. The business had revenue of $5.39 million during the quarter, compared to the consensus estimate of $2.97 million. Tonix Pharmaceuticals had a negative return on equity of 55.19% and a negative net margin of 963.39%.

Tonix Pharmaceuticals Stock Performance

Shares of TNXP stock traded down $0.57 on Thursday, reaching $13.41. The stock had a trading volume of 249,832 shares, compared to its average volume of 377,381. Tonix Pharmaceuticals has a 1 year low of $12.80 and a 1 year high of $69.97. The stock has a market cap of $171.51 million, a P/E ratio of -0.67 and a beta of 1.88. The company has a 50 day simple moving average of $15.76 and a 200 day simple moving average of $19.21.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research report on Wednesday, January 21st. Wall Street Zen upgraded shares of Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, January 17th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $70.00.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Legal & General Group Plc purchased a new position in Tonix Pharmaceuticals in the second quarter worth about $25,000. State of Wyoming bought a new position in shares of Tonix Pharmaceuticals in the 4th quarter worth approximately $27,000. Russell Investments Group Ltd. purchased a new position in shares of Tonix Pharmaceuticals in the third quarter worth approximately $29,000. BNP Paribas Financial Markets purchased a new position in shares of Tonix Pharmaceuticals in the second quarter worth approximately $65,000. Finally, New York State Common Retirement Fund bought a new stake in Tonix Pharmaceuticals during the second quarter valued at approximately $104,000. Institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.